SCHEMBL4836211

SCHEMBL4836211

COC(=O)c1ccc(N)cc1NC(=O)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.54
GAA P10253 2/20 0.54
MAPK1 P28482 1/20 0.54
ALDH1A1 P00352 4/20 0.52
HPGD P15428 4/20 0.52
KDM4E B2RXH2 4/20 0.52
POLB P06746 1/20 0.52
RAB9A P51151 2/20 0.52
NPC1 O15118 1/20 0.52
TRPV1 Q8NER1 3/20 0.51
KCNK2 O95069 2/20 0.51
KCNK10 P57789 2/20 0.51
ABL1 P00519 1/20 0.51
IGF2BP2 Q9Y6M1 1/20 0.49
ELANE P08246 1/20 0.48
PRTN3 P24158 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
TSHR P16473 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4831331 0.88 CFTR (0.57) MAPTGAAMAPK1ALDH1A1HPGD
SCHEMBL4825591 0.86 ELANE (0.55) MAPTGAAALDH1A1HPGDKDM4E
SCHEMBL4801219 0.84 KDM4E (0.61) MAPTGAAMAPK1ALDH1A1HPGD
SCHEMBL4830861 0.81 CFTR (0.52) MAPTGAAMAPK1KDM4ECYP1A2
SCHEMBL4825570 0.81 MAPT (0.53) MAPTALDH1A1HPGDKDM4EPOLB
SCHEMBL17942189 0.80 MAPT (0.64) MAPTGAAMAPK1ALDH1A1HPGD
SCHEMBL4836085 0.80 NPC1 (0.47) MAPTALDH1A1HPGDKDM4EPOLB
SCHEMBL11500979 0.78 MAPT (0.68) MAPTGAAMAPK1ALDH1A1HPGD
SCHEMBL30523269 0.77 IGF2BP2 (0.62) MAPTMAPK1ALDH1A1HPGDKDM4E
SCHEMBL677496 0.76 TRPV1 (0.76) MAPTPOLBRAB9ANPC1TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293790-A1 SUBSTITUTED ARYL OXIMES WYETH (US) 2008-11-27 US disclosed
US-7420083-B2 Substituted aryloximes WYETH (US) 2008-09-02 US disclosed
EP-1663189-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS Wyeth (US) 2006-06-07 EP disclosed
WO-2005030193-A1 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS WYETH (US) 2005-04-07 WO disclosed
US-20050070584-A1 Substituted aryloximes WYETH (US) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070584-A1 Substituted aryloximes AHR, NQO1, AOX1 MAPT 4769/4885GAA 2649/4885MAPK1 3843/4885
US-20080293790-A1 SUBSTITUTED ARYL OXIMES HCCS, AOX1, TET2 MAPT 4362/4885GAA 2012/4885MAPK1 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.